Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
62.933,97
-1,26%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Anavex Life Sciences Corporation (AVXL) Anavex Life Sciences Corporation (AVXL) Notizie

Anavex Life Sciences Corporation

AVXL
3,44
0,05 (1,47%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/4/202411:45PRNUSMay 13, 2024 Deadline: Contact The Gross Law Firm to Join..
19/4/202411:45PRNUSContact The Gross Law Firm by May 13, 2024 Deadline to Join..
16/4/202411:45PRNUSThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff..
12/4/202411:45PRNUSClass Action Filed Against Anavex Life Sciences Corporation..
11/4/202413:30GLOBEAnavex Life Sciences to Present at the Noble Capital Markets..
09/4/202411:45PRNUSClass Action Filed Against Anavex Life Sciences Corporation..
05/4/202411:45PRNUSAnavex Life Sciences Corporation Class Action: The Gross Law..
02/4/202411:45PRNUSShareholders that lost money on Anavex Life Sciences..
29/3/202410:45PRNUSLost Money on Anavex Life Sciences Corporation(AVXL)? Join..
26/3/202410:45PRNUSInvestors who lost money on Anavex Life Sciences..
25/3/202412:30GLOBEAnavex Life Sciences to Present at the 23rd Annual Needham..
22/3/202410:45PRNUSAVXL LAWSUIT ALERT: The Gross Law Firm Notifies Anavex Life..
18/3/202412:30GLOBEAnavex Life Sciences Initiates Placebo-Controlled U.S. Phase..
26/2/202413:30GLOBEAnavex Life Sciences to Present at the 44th Annual TD Cowen..
23/2/202412:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202412:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202412:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202412:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202412:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/2/202413:30GLOBEAnavex Life Sciences Reports Fiscal 2024 First Quarter..
01/2/202413:30GLOBEAnavex Life Sciences to Announce Fiscal 2024 First Quarter..
25/1/202423:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202413:30GLOBEAnavex Life Sciences Reports Publication of ANAVEX®3-71 in..
16/1/202413:30GLOBEAnavex Life Sciences Announces U.S. Phase 2 Clinical Trial..
13/1/202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:30GLOBEAnavex Life Sciences Announces Grant of U.S. Patent Covering..
03/1/202413:30GLOBEAnavex to Present at the 42nd Annual J.P. Morgan Healthcare..
02/1/202414:00GLOBEAnavex Life Sciences Provides an Update on Rett Syndrome..
20/12/202313:30GLOBEAnavex Announces First Entire Clinical Gene Pathway Data of..
19/12/202313:30GLOBEAnavex Received Agreement from the Committee for Medicinal..
27/11/202322:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/11/202314:00GLOBEAnavex Life Sciences Reports Fiscal 2023 Year End Financial..
27/11/202312:29IHMARKETNEWSMonday’s Wall Street Highlights: Walmart, Disney, Lloyds..
24/11/202314:00GLOBEAnavex Life Sciences to Announce Fiscal 2023 Year End..
22/11/202314:00GLOBEAnavex Life Sciences Announces Grant of U.S. Patent Covering..
20/11/202314:00GLOBEAnavex Initiates Regulatory Submission of Oral Blarcamesine..
06/11/202314:00GLOBEAnavex Life Sciences Appoints Senior VP of Regulatory..
25/10/202314:00GLOBEAnavex Life Sciences Reports New Publication in Scientific..
14/9/202313:30GLOBEAnavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in..
12/9/202313:30GLOBEAnavex Announces Appointment of Dr. Marwan N Sabbagh, MD as..
08/8/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:30GLOBEAnavex Life Sciences Reports Fiscal 2023 Third Quarter..
07/8/202313:30GLOBEAnavex Life Sciences Reports Publication of ANAVEX®3-71 in..
02/8/202313:30GLOBEAnavex Life Sciences to Present at the BTIG Virtual..
01/8/202313:30GLOBEAnavex Life Sciences to Announce Fiscal 2023 Third Quarter..
28/6/202313:30GLOBELong-term Clinical Study Demonstrates Disease Modifying..
27/6/202313:30GLOBEAnavex Life Sciences and Partex Group Announce Strategic..
20/6/202313:30GLOBEAnavex Life Sciences to Present at the H.C. Wainwright 4th..
15/6/202313:30GLOBEANAVEX®2-73 (blarcamesine) Receives Compassionate Use..
Apertura: 3,40 Min: 3,37 Max: 3,48
Chiusura: 3,39

La tua Cronologia

NASDAQ
AVXL
Anavex Life Sciences
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network